Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b' Open Label, Single Arm, Multicenter Trial to Evaluate the Safety, Tolerance, Response Rate and Immunological Effects of Repeated Intratumoral Injections of Adenoviral Transduced Autologous Dendritic Cells Engineered to Express hIL-12(INXN-3001) in Response to an Oral Activator Ligand Administered in Intra-Patient Escalating Doses in Patients With Unresectable Stage III C or IV Malignant Melanoma.

Next Previous
Search
Trial Profile

Phase 1b' Open Label, Single Arm, Multicenter Trial to Evaluate the Safety, Tolerance, Response Rate and Immunological Effects of Repeated Intratumoral Injections of Adenoviral Transduced Autologous Dendritic Cells Engineered to Express hIL-12(INXN-3001) in Response to an Oral Activator Ligand Administered in Intra-Patient Escalating Doses in Patients With Unresectable Stage III C or IV Malignant Melanoma.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INXN 3001 (Primary) ; Veledimex (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Alaunos Therapeutics

Most Recent Events

  • 17 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 16 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 23 Feb 2012 Company (ZIOPHARM Oncology) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top